Company intelligence / Profile preview

Dux Healthcare

Haifa, Israel

Ownership: Private
Development stage: Other

Overview

Dux Healthcare has developed an AI-powered platform that predicts epileptic seizures 30–60 minutes in advance based on EEG and ECG signals. Validated in clinical cohorts with a false positive of approximately one every two weeks, Dux is entering clinical trials with FDA pre-submission and targets a US commercial launch in 2027.[1]

Therapeutic areas: Neurology
Modalities: DeviceSoftwareArtificial intelligence
Industry: Physiological Monitoring

Beyond the preview

Go deeper on Dux Healthcare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dux Healthcare.

Explore the full profile